ASCO 2020: Anti-Androgenic Cabozantinib Plus Nivolumab a Promising Combination in Endometrial Cancer
Activity was even apparent in aggressive forms of endometrial cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.